Understanding Huntington's Disease: Causes, Symptoms, and Treatment Options

Introduction

Huntington's Disease (HD) casts a long and devastating shadow across generations, profoundly impacting not only the individuals who inherit it but also their entire families. The social consequences are far-reaching, affecting relationships, community involvement, and overall well-being, often leading to complex emotional and psychological dynamics within families. Feelings of guilt, fear, and uncertainty are common as family members grapple with the implications of this inherited disorder. This can lead to significant shifts in family roles and responsibilities, creating emotionally and practically challenging adjustments for everyone involved. The sudden behavioral changes and the eventual loss of a loved one's former self can be incredibly confusing and emotionally taxing. Beyond the personal toll, the financial strain due to loss of employment and the increasing need for specialized care can further burden families. The emotional impact on individuals is equally significant, with depression, irritability, sadness, and even thoughts of suicide being common. Understanding the multifaceted impact of HD on families and individuals is the first crucial step in addressing this challenging condition.

Unraveling the Mystery: The Genetic Roots of Huntington's Disease

Huntington's Disease is a hereditary neurodegenerative disorder, named after Dr. George Huntington, who first described it in 187. The genetic basis of HD was discovered in 1993 by a collaborative group of researchers. The disease is caused by a mutation in a single gene, known as the HTT gene, located on chromosome 4. This gene contains a sequence of three DNA building blocks – cytosine, adenine, and guanine (CAG) – that are repeated multiple times. In most individuals, the number of CAG repeats ranges from seven to 35. However, in people with Huntington's Disease, this CAG sequence is abnormally expanded.

The number of CAG repeats directly correlates with the risk and age of onset of HD. Individuals with fewer than 27 repeats are not typically at risk of developing the disease. Those with 27 to 35 repeats are generally not likely to develop symptoms but may have a slightly increased risk of their children inheriting a larger repeat number. A repeat range of 36 to 39 is considered to have reduced penetrance, meaning some individuals with this range may develop symptoms later in life, while others may not. Individuals with 40 or more CAG repeats will almost always develop Huntington's Disease during their lifetime. The length of the CAG repeat tends to be inversely related to the age of onset, with a higher number of repeats often leading to earlier symptom development. In the less common juvenile form of Huntington's Disease, which appears in childhood or adolescence, individuals typically have more than 60 CAG repeats.

Huntington's Disease follows an autosomal dominant inheritance pattern. This means that only one copy of the mutated HTT gene is sufficient to cause the disorder. Therefore, every child of a parent with Huntington's Disease has a 50% chance of inheriting the mutated gene and subsequently developing the condition. If a child does not inherit the mutated gene, they will not develop the disease and cannot pass it on to future generations. Interestingly, the number of CAG repeats can sometimes increase when passed from a father to a child, a phenomenon known as anticipation, which can result in an earlier age of onset in subsequent generations. Recent research has also highlighted the role of somatic expansion, where the number of CAG repeats within the HTT gene can slowly increase over decades in specific brain cells. This process may contribute to the adult-onset nature of the disease, as the repeat number might reach a toxic threshold later in life.

Table 1: CAG Repeat Ranges and Huntington's Disease

The Many Faces of HD: Understanding the Symptoms

Huntington's Disease is characterized by a wide spectrum of symptoms that typically emerge in adulthood, usually between the ages of 30 and 50, although they can appear at any age. The initial symptoms can vary significantly from person to person, and their severity tends to change throughout the course of the disease. These symptoms broadly fall into three categories: movement disorders, cognitive decline, and psychiatric issues.

One of the most recognizable features of Huntington's Disease is the presence of involuntary movements known as chorea. Derived from the Greek word for "dance," chorea manifests as brief, abrupt, irregular, and unpredictable jerking or writhing movements that can affect the limbs, face, and tongue. Initially, chorea might appear as general restlessness, fidgetiness, or minor, unintentional movements. As the disease progresses, these movements can become more pronounced and interfere with voluntary actions, impacting speech, swallowing, posture, and gait. However, it is important to note that not everyone with HD experiences chorea, and some may instead develop rigidity, known as akinesia, characterized by muscle stiffness and reduced movement. Other movement-related symptoms can include muscle rigidity or contracture, slow or unusual eye movements, and difficulties with balance and coordination, increasing the risk of falls . Some individuals may also experience dystonia, which involves sustained, involuntary muscle contractions that can lead to abnormal postures.

Cognitive decline is another core feature of Huntington's Disease, often significantly impacting an individual's daily life. Early cognitive symptoms may include difficulties with memory, learning new information, impaired judgment, and trouble with tasks requiring planning and decision-making. As the disease progresses, individuals may experience slowed thinking, difficulty concentrating on more than one task at a time, and delayed processing skills. They may also exhibit a lack of flexibility in their thinking, getting "stuck" on a particular thought or action (perseveration), and struggle with organizing, prioritizing, and focusing on tasks. Impulsivity and a lack of awareness of their own abilities and behaviors are also common. In later stages, cognitive impairments can advance to dementia, affecting various cognitive functions. The frontal lobe of the brain, responsible for executive functions like organizing, prioritizing, impulse control, and problem-solving, is particularly affected in HD, contributing to these cognitive challenges.

Psychiatric issues are frequently observed in individuals with Huntington's Disease and can sometimes precede the onset of motor symptoms. Depression is the most common psychiatric condition associated with HD, often occurring due to brain damage and changes in brain function, rather than simply being a reaction to the diagnosis. Symptoms of depression can include irritability, sadness, apathy, social withdrawal, trouble sleeping, fatigue, loss of energy, and thoughts of death or suicide. Other common mental health conditions include obsessive-compulsive disorder, mania (characterized by elevated mood and hyperactivity), and bipolar disorder. Behavioral changes such as increased irritability, impulsivity, aggression, and apathy are also common. Individuals with HD may also experience mood swings, anxiety, and personality changes. Notably, the risk of suicide is significantly higher in individuals with Huntington's Disease, particularly before diagnosis and during periods of loss of independence.

Juvenile Huntington's Disease, which onsets before the age of 20, often presents with symptoms that differ from the adult-onset form. While individuals with adult-onset HD typically exhibit chorea as an early symptom, children and young people with juvenile HD are less likely to experience these involuntary movements initially. Instead, they are more prone to muscle contractions and stiffness (rigidity). Epilepsy, or seizures, is also more common in juvenile HD, particularly in younger children. Other early signs in juvenile HD can include behavioral changes, such as difficulty concentrating and a sudden drop in school performance. Physical symptoms may involve contracted and rigid muscles affecting walking, slight uncontrollable movements (tremors), frequent falls or clumsiness, and slow movements similar to those seen in Parkinson's disease. Juvenile HD tends to progress more rapidly than the adult-onset form, often leading to death within 10 to 15 years after symptoms appear.

Living with Huntington's: Current Treatment Strategies

Currently, there is no cure for Huntington's Disease, and no treatments are available to halt or reverse the progression of the disease. The primary focus of current treatment strategies is to manage the various symptoms and improve the quality of life for individuals living with HD. This often involves a multidisciplinary team of healthcare professionals, including neurologists, psychiatrists, therapists, and social workers .

Several medications are available to help control the involuntary movements associated with Huntington's Disease, particularly chorea. Tetrabenazine (Xenazine), deutetrabenazine (Austedo), and valbenazine (Ingrezza) are FDA-approved medications that can suppress these jerking and writhing movements by decreasing the levels of dopamine in the brain. While effective in managing chorea, these medications do not affect the underlying progression of the disease and can have potential side effects such as drowsiness, restlessness, and an increased risk of depression. Other medications that may be used to help suppress chorea include antipsychotic drugs like haloperidol, fluphenazine, olanzapine (Zyprexa), and aripiprazole (Abilify, Aristada). These drugs can also help control hallucinations, delusions, and violent outbursts that may occur in some individuals with HD. However, antipsychotics can also have significant side effects, including worsening dystonia and causing slow movements resembling Parkinson's disease. Other medications like amantadine (Gocovri), levetiracetam (Keppra, Spritam), and clonazepam (Klonopin) may also be used to manage chorea, although their effectiveness and side effects can vary.

Managing the psychiatric symptoms of Huntington's Disease is equally important for improving the well-being of affected individuals. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) like citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), and sertraline (Zoloft), are commonly prescribed to treat depression and may also help with obsessive-compulsive symptoms. Antipsychotic medications, including quetiapine (Seroquel) and olanzapine (Zyprexa), can be used to manage violent outbursts, agitation, and other psychotic symptoms. Mood-stabilizing medications, such as anti-seizure drugs like divalproex (Depakote), carbamazepine (Tegretol, Carbatrol, Epitol), and lamotrigine (Lamictal), can help prevent the highs and lows associated with bipolar disorder and manage mood swings. The choice of medication depends on the specific psychiatric condition and symptoms, and careful monitoring for side effects is essential.

In addition to medications, various supportive therapies play a crucial role in helping individuals adapt to the changes brought about by Huntington's Disease. Physical therapy is vital for maintaining strength, flexibility, balance, and coordination, and physical therapists can also provide guidance on safe exercises and the use of mobility aids like walkers or wheelchairs. Occupational therapy focuses on helping individuals and their families and caregivers use assistive devices and strategies to improve function in daily activities such as bathing, dressing, and eating. Speech therapy is essential for addressing difficulties with speaking clearly and swallowing safely, and speech therapists can also teach individuals how to use communication devices if needed. Psychotherapy, including talk therapy and cognitive behavioral therapy (CBT), can be beneficial in managing behavioral and emotional symptoms, helping individuals cope with the psychological impact of the disease. Furthermore, creating a structured and calm environment, establishing routines, and providing reminders can help manage cognitive difficulties.

A Glimmer of Hope: Emerging Therapies and Research Advancements

The field of Huntington's Disease research is rapidly evolving, with significant attention focused on developing therapies that can target the underlying genetic cause and slow or halt disease progression. One of the most promising areas of investigation involves antisense oligonucleotides (ASOs). ASOs are synthetic, single-stranded DNA molecules that are chemically modified to enhance their stability and effectiveness in the body. These molecules are designed to bind to the messenger RNA (mRNA) of the HTT gene, the genetic blueprint used to create the huntingtin protein. By binding to the mRNA, ASOs can either trigger its degradation or block its translation into the huntingtin protein, thus lowering the overall levels of the protein, including the toxic mutant form. ASOs are particularly well-suited for treating neurological disorders like HD because they can distribute broadly throughout the central nervous system and are taken up by brain cells without needing a special delivery system. Several ASOs are currently being evaluated in clinical trials for Huntington's Disease, including tominersen (RG6042), which is being tested in the GENERATION-HD2 trial. Previous trials with tominersen showed a reduction in mutant huntingtin protein levels, and further analysis suggested potential benefits for younger individuals with earlier stages of the disease. Another ASO, WVE-003, is being investigated in the SELECT-HD trial. Research is also exploring the development of allele-specific ASOs that could selectively target the mutated copy of the HTT gene while leaving the healthy copy relatively untouched, potentially minimizing side effects. Recent studies have even shown that some ASOs can potentially stop the expansion of the CAG repeats in lab-grown neurons and reduce the targeted protein in mice, suggesting a disease-modifying effect.

Beyond ASOs, other gene-targeting approaches are also under active investigation. RNA interference (RNAi) therapies utilize small RNA molecules to silence specific genes, including the mutant HTT gene. Gene editing technologies like CRISPR and TALEN offer the potential to directly edit the DNA sequence of the HTT gene, correcting the mutation. While these technologies are still largely in preclinical development for HD, advancements in their application to other genetic disorders offer hope for their future use in treating Huntington's Disease. Researchers are also exploring innovative strategies like peptide-brush polymers, which act as a shield to prevent the mutant huntingtin protein from aggregating and causing cellular damage. Studies in mice have shown promising results with this approach, successfully rescuing neurons and reversing symptoms.

Ongoing research efforts are crucial for advancing our understanding of Huntington's Disease and developing effective treatments. Clinical trials are essential for evaluating the safety and efficacy of new therapies, and participation in these trials is vital for progress. Resources like the HD Trial Finder and Enroll-HD help connect individuals and families with ongoing clinical studies. Biomarker research is also critical for understanding disease progression and measuring the impact of potential treatments. Studies like HDClarity focus on collecting cerebrospinal fluid to identify biomarkers, and research is underway to validate biomarkers like neurofilament light chain (NfL), which can signal disease progression even before symptoms appear. Scientists are also actively investigating the mechanisms underlying Huntington's Disease, including somatic instability (the tendency of CAG repeats to expand in certain brain cells) and identifying genetic modifiers that can influence the age of onset and rate of disease progression. This deeper understanding of the disease at a molecular and cellular level is paving the way for the development of more targeted and effective therapies.

More Than Medicine: The Vital Role of Patient Advocacy and Support

Patient advocacy plays an indispensable role in the Huntington's Disease community. Organizations like the Huntington's Disease Society of America (HDSA) and the European Huntington's Disease Network (EHDN) provide crucial support, education, and resources for individuals and families affected by HD. They advocate for increased research funding, improved clinical care, and greater awareness of the disease within the medical community and the general public . Support groups offer a vital source of emotional support and a space for individuals and families to connect with others who understand their experiences and share valuable advice. Given the significant mental health challenges faced by the HD community, patient advocacy organizations also play a critical role in raising awareness about these issues and promoting access to mental health services. Patient advocates actively contribute to the research process by participating in Patient-Focused Drug Development meetings with regulatory agencies like the FDA, engaging in clinical trials, and collaborating with researchers to ensure that the perspectives and needs of the HD community are integrated into the development of new therapies. Initiatives like the HD Coalition for Patient Engagement (HD-COPE) provide a platform for families affected by HD to have a direct voice in clinical research, ensuring that research is conducted "with" or "by" the community, rather than just "to" or "about" them. The dedication and tireless efforts of patient advocates are essential in driving progress towards effective treatments and ultimately a cure for Huntington's Disease.

Conclusion: Embracing Hope in the Face of Adversity

Huntington's Disease remains a formidable challenge, impacting individuals and families in profound and lasting ways. However, the remarkable progress in scientific research over the past few decades offers a growing sense of hope. The identification of the causative gene, the increasing understanding of the disease mechanisms, and the development of promising therapeutic strategies like antisense oligonucleotides represent significant strides forward. The ongoing commitment of researchers, clinicians, patient advocacy organizations, and the resilient Huntington's Disease community continues to drive the pursuit of effective treatments and a future free from the grip of this devastating disorder. While the journey is ongoing, the collective efforts and unwavering hope offer a beacon of light for those affected by Huntington's Disease.

Works cited

1. Social Impacts | Huntington's Victoria, fecha de acceso: marzo 21, 2025, https://huntingtonsvic.org.au/social-impacts/
2. Families Affected by Huntington's Disease Report Difficulties in Communication, Emotional Involvement, and Problem Solving, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5682576/
3. Living in a Family with HD - Huntington's Disease Youth Organization, fecha de acceso: marzo 21, 2025, https://www.hdyo.org/a/62-living-in-a-family-with-hd
4. Huntington's in the family, fecha de acceso: marzo 21, 2025, https://www.hda.org.uk/get-involved/campaigning/awareness-month-20241/huntingtons-in-the-family/
5. Huntington's disease - Symptoms and causes - Mayo Clinic, fecha de acceso: marzo 21, 2025, https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117
6. Huntington's disease - Symptoms - NHS, fecha de acceso: marzo 21, 2025, https://www.nhs.uk/conditions/huntingtons-disease/symptoms/
7. About Huntington's Disease and Related Disorders | Johns Hopkins Medicine, fecha de acceso: marzo 21, 2025, https://www.hopkinsmedicine.org/psychiatry/specialty-areas/huntingtons-disease/patient-family-resources/education-whatis
8. Huntington Disease - StatPearls - NCBI Bookshelf, fecha de acceso: marzo 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559166/
9. Huntingtin - Wikipedia, fecha de acceso: marzo 21, 2025, https://en.wikipedia.org/wiki/Huntingtin
10. Huntington's Disease | National Institute of Neurological Disorders and Stroke, fecha de acceso: marzo 21, 2025, https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease
11. The Huntington Gene - UC Davis Huntington's Disease Center of Excellence, fecha de acceso: marzo 21, 2025, https://health.ucdavis.edu/huntingtons/genetic-change.html
12. medlineplus.gov, fecha de acceso: marzo 21, 2025, https://medlineplus.gov/genetics/gene/htt/#:~:text=People%20with%20the%20adult%2Donset,more%20than%2060%20CAG%20repeats.
13. Huntington's disease - Genetics - MedlinePlus, fecha de acceso: marzo 21, 2025, https://medlineplus.gov/genetics/condition/huntingtons-disease/
14. Study finds surprising way that genetic mutation causes Huntington's disease, transforming understanding of the disorder | Broad Institute, fecha de acceso: marzo 21, 2025, https://www.broadinstitute.org/news/study-finds-surprising-way-genetic-mutation-causes-huntingtons-disease-transforming
15. Huntington's Disease: Who Will Inherit the Gene? - University of Utah Health, fecha de acceso: marzo 21, 2025, https://healthcare.utah.edu/healthfeed/2022/03/huntingtons-disease-who-will-inherit-gene
16. medlineplus.gov, fecha de acceso: marzo 21, 2025, https://medlineplus.gov/genetics/condition/huntingtons-disease/#:~:text=Inheritance&text=This%20condition%20is%20inherited%20in,gene%20from%20one%20affected%20parent.
17. Chorea & Huntington's Disease - International Parkinson and Movement Disorder Society, fecha de acceso: marzo 21, 2025, https://www.movementdisorders.org/MDS/About/Movement-Disorder-Overviews/Chorea--Huntingtons-Disease.htm
18. New Understanding of How Genetic Mutation Causes Huntington's Disease, fecha de acceso: marzo 21, 2025, https://hms.harvard.edu/news/new-understanding-how-genetic-mutation-causes-huntingtons-disease
19. Huntington's disease - NHS, fecha de acceso: marzo 21, 2025, https://www.nhs.uk/conditions/huntingtons-disease/
20. Huntington's disease | NHS inform, fecha de acceso: marzo 21, 2025, https://www.nhsinform.scot/illnesses-and-conditions/brain-nerves-and-spinal-cord/huntingtons-disease/
21. www.mayoclinic.org, fecha de acceso: marzo 21, 2025, https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117#:~:text=The%20movement%20disorders%20related%20to,ability%20to%20make%20voluntary%20movements.
22. Huntington's disease - Wikipedia, fecha de acceso: marzo 21, 2025, https://en.wikipedia.org/wiki/Huntington%27s_disease
23. memory.ucsf.edu, fecha de acceso: marzo 21, 2025, https://memory.ucsf.edu/dementia/huntington-disease#:~:text=Early%20in%20the%20disease%2C%20cognitive,intellectual%20tasks%20become%20increasingly%20difficult.
24. Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF - PMC - PubMed Central, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8029162/
25. Huntington's Disease | Memory and Aging Center, fecha de acceso: marzo 21, 2025, https://memory.ucsf.edu/dementia/huntington-disease
26. Cognitive impairment - Huntington's Disease Association, fecha de acceso: marzo 21, 2025, https://www.hda.org.uk/get-involved/campaiging/huntingtons-disease-awareness-month-2023/cognitive-impairment/
27. Cognitive Symptoms - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/what-is-hd/cognitive-symptoms/
28. Neuropsychiatry of Huntington's disease - PMC - PubMed Central, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3181855/
29. Psychiatric disorders in preclinical Huntington's disease - PMC - PubMed Central, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2117854/
30. Behavioral / Psychiatric Symptoms - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/what-is-hd/behavioral-psychiatric-symptoms/
31. secure.ssa.gov, fecha de acceso: marzo 21, 2025, https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022923
32. Huntington's Disease | Johns Hopkins Medicine, fecha de acceso: marzo 21, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/huntingtons-disease
33. Living with Huntington's Disease: A Conversation on Advocacy ..., fecha de acceso: marzo 21, 2025, https://c-path.org/living-with-huntingtons-disease-a-conversation-on-advocacy-mental-health-and-self-care/
34. Juvenile Huntington's disease, fecha de acceso: marzo 21, 2025, https://www.hda.org.uk/professionals-and-training/about-huntingtons-disease/juvenile-huntingtons-disease/
35. Juvenile Huntington's disease, fecha de acceso: marzo 21, 2025, https://www.hda.org.uk/information-and-support/huntingtons-disease/juvenile-huntingtons-disease/
36. Huntington's disease - Diagnosis and treatment - Mayo Clinic, fecha de acceso: marzo 21, 2025, https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/diagnosis-treatment/drc-20356122
37. Expert perspectives: The future of Huntington's disease management and treatment, fecha de acceso: marzo 21, 2025, https://www.medicalnewstoday.com/articles/future-of-huntingtons-disease-treatment
38. Huntington's Disease | ASGCT - American Society of Gene & Cell Therapy |, fecha de acceso: marzo 21, 2025, https://patienteducation.asgct.org/disease-treatments/huntingtons-disease
39. www.mayoclinic.org, fecha de acceso: marzo 21, 2025, https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/diagnosis-treatment/drc-20356122#:~:text=Medicines%20to%20control%20movement%20include,a%20result%20of%20Huntington's%20disease.
40. Chorea: What It Is, Causes, Treatment & Risk Factors - Cleveland Clinic, fecha de acceso: marzo 21, 2025, https://my.clevelandclinic.org/health/symptoms/21192-chorea
41. Chorea in Adults Treatment & Management: Medical Care, Surgical Care, fecha de acceso: marzo 21, 2025, https://emedicine.medscape.com/article/1149854-treatment
42. Therapies In Pipeline - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/hd-research/therapies-in-pipeline/
43. www.mayoclinic.org, fecha de acceso: marzo 21, 2025, https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/diagnosis-treatment/drc-20356122#:~:text=Other%20medicines%20that%20may%20help,)%20and%20clonazepam%20(Klonopin).
44. Current and Possible Future Therapeutic Options for Huntington's Disease - PMC, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9125092/
45. ASO versus AAV gene therapy strategies in Huntington's disease - YouTube, fecha de acceso: marzo 21, 2025, https://www.youtube.com/watch?v=x-ZrrBgLMgE
46. Antisense Oligonucleotide Therapy: From Design to the Huntington ..., fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8899000/
47. Advances in gene and cellular therapeutic approaches for Huntington's disease, fecha de acceso: marzo 21, 2025, https://academic.oup.com/proteincell/advance-article/doi/10.1093/procel/pwae042/7731066
48. Clinical trial for Huntington Disease (HD)-Genentech A Me, fecha de acceso: marzo 21, 2025, https://genentech-clinicaltrials.com/en/trials/neurodegenerative-disorder/hd/a-study-to-evaluate-the-safety--biomarkers--and-efficac-41200.html
49. Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington's Disease (S56.001) - Neurology.org, fecha de acceso: marzo 21, 2025, https://www.neurology.org/doi/10.1212/WNL.88.16_supplement.S56.001
50. Oligonucleotide stops gene expansion process that drives Huntington's disease: study, fecha de acceso: marzo 21, 2025, https://www.fiercebiotech.com/research/oligonucleotide-stops-gene-expansion-process-drives-huntingtons-disease-study
51. Oligonucleotide therapeutic approaches for Huntington disease - JCI, fecha de acceso: marzo 21, 2025, https://www.jci.org/articles/view/45130
52. 2024: Year in Review - HDBuzz - Huntington's disease research news., fecha de acceso: marzo 21, 2025, https://en.hdbuzz.net/402
53. New Huntington's treatment prevents protein aggregation ..., fecha de acceso: marzo 21, 2025, https://news.northwestern.edu/stories/2024/11/new-huntingtons-treatment-prevents-protein-aggregation/
54. Research Program | Johns Hopkins Medicine, fecha de acceso: marzo 21, 2025, https://www.hopkinsmedicine.org/psychiatry/specialty-areas/huntingtons-disease/research
55. HDBuzz - Huntington's disease research news., fecha de acceso: marzo 21, 2025, https://hdbuzz.net/
56. Enroll in a Clinical Trial - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/hd-research/enroll-in-a-clinical-trial/
57. Join a Huntington Disease Clinical Trial with HSG | Huntington Study Group, fecha de acceso: marzo 21, 2025, https://huntingtonstudygroup.org/join-a-study/
58. Huntington's Disease | Programs & Pipeline - uniQure, fecha de acceso: marzo 21, 2025, https://www.uniqure.com/programs-pipeline/huntingtons-disease
59. Huntington's Disease - Family Caregiver Alliance, fecha de acceso: marzo 21, 2025, https://www.caregiver.org/resource/huntingtons-disease/
60. HD Patients and Families - European Huntington's Disease Network, fecha de acceso: marzo 21, 2025, https://ehdn.org/hd-patients-families/
61. Advocacy Recruiting for Huntington's Disease Clinical Trials - PMC, fecha de acceso: marzo 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3082401/
62. Advocating for Yourself - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/disability-tips/advocating-for-yourself/
63. HD Cope - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/hd-research/hd-cope/
64. Community & Social Support - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/find-help/community-social-support/
65. Huntington's Disease Society of America (HDSA) - HeyPeers, fecha de acceso: marzo 21, 2025, https://www.heypeers.com/organizations/128
66. Resources | Johns Hopkins Medicine, fecha de acceso: marzo 21, 2025, https://www.hopkinsmedicine.org/psychiatry/specialty-areas/huntingtons-disease/patient-family-resources/resources
67. HDSA Support Groups - Huntington's Disease Society of America, fecha de acceso: marzo 21, 2025, https://hdsa.org/find-help/community-social-support/hdsa-support-groups/